Fulcrum Therapeutics share price logo

Fulcrum Therapeutics

NASDAQ: FULC

Small Cap

$3.73

+0.03

(+0.81%)

as on

Fulcrum Therapeutics Stock Performance

as on October 21, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $3.69
    $3.75
    downward going graph

    1.07%

    Downside

    0.54%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $2.83
    $15.74
    downward going graph

    24.13%

    Downside

    321.98%

    Upside

    downward going graph

Fulcrum Therapeutics share price movements today

Previous Close
$3.70
Open
$3.71
Volume
1.5M
Market Cap
$278.8M
Day's Low - High
$3.69 - $3.75
52 Week Low - High
$2.83 - $15.74

Fulcrum Therapeutics Historical Returns

1 Month Return
-1.6 %
3 Month Return
+ 2.21 %
1 Year Return
-59.87 %
3 Year Return
+ 1.65 %
5 Year Return
-84.24 %

Fulcrum Therapeutics Stock Fundamentals & Key Indicators

Check Fulcrum Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$278.8M

EPS (TTM)

-1.21

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-3.02

Industry PE ratio

-7.03

PEG Ratio

-7.96

EBITDA

-77.5M

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

-28.54%

Fulcrum Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Fulcrum Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Neutral$278.8M-84.24%-3.020.00%0.00%
Neutral$87.0B-31.87%-27.32-12.57%0.00%
StrongBuy$126.7B170.61%28.8586.04%0.00%
Buy$81.4B38.98%18.8884.86%0.47%

Stock Returns calculator for Fulcrum Therapeutics Stock including INR - Dollar returns

The Fulcrum Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

Fulcrum Therapeutics investment value today

Current value as on today

₹43,703

Returns

-₹56,297

(-56.3%)

Returns from Fulcrum Therapeutics Stock

-₹59,544 (-59.54%)

Dollar Impact

₹3,248 (+3.25%)

Analyst Recommendation on Fulcrum Therapeutics Stock

Based on 1 analysts

HOLD

0.00%

Buy

100.00%

Hold

0.00%

Sell

Based on 1 analysts, 100% of analysts recommend a 'HOLD' rating for Fulcrum Therapeutics. Average target price of $3.67

Fulcrum Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Fulcrum Therapeutics.

What analysts predicted

-1.63%DOWNSIDE

Target Price

$3.67

Current Price

$3.73

Analyzed by

1 Analysts

Target

$3.67

Fulcrum Therapeutics target price $3.67, a slight downside of -1.63% compared to current price of $3.73. According to 1 analysts rating.

Indian Investors' Interest in Fulcrum Therapeutics Stock

Search interest for Fulcrum Therapeutics Stock has decreased by -57% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-57% versus previous 30 day period

Fulcrum Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
-
80
-
-
-
-
-
-
-
-
Gross Profit
0
62
-14
0
-13
0
-14
0
0
0
Operating Income
-29
52
-25
-19
-20
-19
-21
-22
-22
-19
EBITDA
-26
55
-22
-16
-17
-16
-19
-19
-18
-19
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-26
55
-21
-16
-17
-17
-19
-20
-18
-26
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-26
55
-21
-16
-17
-17
-19
-20
-18
-26
Net Profit Margin
0.00%
78.42%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

Fulcrum Therapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
-
8
19
6
2
80
-
Gross Profit
0
-1
-2
-50
-50
-70
-68
78
-1
Operating Income
-22
-33
-58
-71
-81
-112
-110
-21
-84
EBITDA
-22
-32
-80
-69
-78
-109
-95
-18
-73
Interest Expense
-
-
-
-
-
-
-
-
-
Depreciation
0
1
2
2
2
2
2
1
1
Income Before Tax
-22
-32
-82
-70
-80
-109
-97
-9
-74
Income Tax Expense
0
-
-
-
-
-
-
-
-
Net Income
-22
-32
-82
-70
-80
-109
-97
-9
-74
Net Profit Margin
0.00%
0.00%
0.00%
-569.18%
-263.73%
-1110.69%
100.00%
20.77%
0.00%

Fulcrum Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-26
55
-21
-16
-17
-17
-19
-20
-18
-26
Operating Cash Flow
-25
58
-19
-16
-15
-13
-14
-16
-18
-16
Investing Cash Flow
38
-12
4
2
0
13
18
-1
-128
13
Financing Cash Flow
1
0
0
0
-
0
0
168
0
0
Change in Cash
14
46
-14
-14
-16
0
4
150
-147
-1

Fulcrum Therapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-22
-32
-82
-70
-80
-109
-97
-9
-74
Operating Cash Flow
-20
-22
-39
-53
-78
-97
-90
-2
-60
Investing Cash Flow
-1
-8
0
-57
-129
12
-36
32
30
Financing Cash Flow
17
105
64
71
186
84
118
2
168
Change in Cash
-4
73
23
-39
-21
0
-9
32
139

Global Institutional Holdings in Fulcrum Therapeutics

Check out the Institutions with significant holdings in Fulcrum Therapeutics.

Funds
Holdings
Peter Kolchinsky
7.93%
Vanguard
4.46%
iShares
4.46%
VANGUARD INDEX FUNDS
3.44%
Fidelity Salem Street Trust
0.88%

Insights on Fulcrum Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 3 quarters, 759.0K → 80.0M (in $), with an average increase of 55.9% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 725.4% return, outperforming this stock by 787.3%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Moderna, Inc. Common Stock has given 182.2% return, outperforming this stock by 180.6%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, -18.89M → -26.17M (in $), with an average decrease of 38.6% per quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 6 months, FULC stock has moved down by -50.9%

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.
OrganisationFulcrum Therapeutics
Headquarters26 Landsdowne Street, Cambridge, MA, 02139, US
IndustryBiotechnology
CEOAlexander C. Sapir

Key Management of Fulcrum Therapeutics

Name

Title

Mr. Alan A. Musso C.M.A., CPA

CFO, Treasurer & Principal Accounting Officer

Mr. Curtis G. Oltmans J.D.

Chief Legal Officer, Head of External Affairs & Corporate Secretary

Dr. Bradley E. Bernstein M.D., Ph.D.

Founder

Dr. Rudolf Jaenisch M.D., Ph.D.

Founder

Dr. Iain Fraser DPHIL

Senior Vice President of Early Development

Bobby Riehle Ph.D.

Head of Program Strategy & Vice President

Mr. Alexander C. Sapir

CEO, President & Director

Dr. Tsun-Huei Lee M.D., Ph.D.

Founder

Dr. Danny Reinberg

Founder

Dr. Michael R. Green

Founder

FAQs

What is Fulcrum Therapeutics share price today?

Fulcrum Therapeutics share price today is $3.73 as on at the close of the market. Fulcrum Therapeutics share today touched a day high of $3.75 and a low of $3.69.

What is the 52 week high and 52 week low for Fulcrum Therapeutics share?

Fulcrum Therapeutics share touched a 52 week high of $15.74 on and a 52 week low of $2.83 on . Fulcrum Therapeutics stock price today i.e. is closed at $3.73,which is 76.30% down from its 52 week high and 31.80% up from its 52 week low.

What is Fulcrum Therapeutics's market capitalisation today?

Fulcrum Therapeutics market capitalisation is $0.00T as on .

How to invest in Fulcrum Therapeutics Stock (FULC) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Fulcrum Therapeutics on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Fulcrum Therapeutics Stock (FULC) from India?

Indian investors can start investing in Fulcrum Therapeutics (FULC) shares with as little as ₹94.93000030517578 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹949.30 in Fulcrum Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Fulcrum Therapeutics share’s latest price of $3.73 as on October 21, 2026 at 1:29 am IST, you will get 2.6810 shares of Fulcrum Therapeutics. Learn more about fractional shares .

What are the returns that Fulcrum Therapeutics has given to Indian investors in the last 5 years?

Fulcrum Therapeutics stock has given -84.24% share price returns and 26.89% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?